Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Should You Buy Blueprint Medicines (BPMC) After Golden Cross?
10:56am, Thursday, 06'th Feb 2025
After reaching an important support level, Blueprint Medicines Corporation (BPMC) could be a good stock pick from a technical perspective. BPMC recently experienced a "golden cross" event, which saw i
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
08:00am, Wednesday, 05'th Feb 2025
CAMBRIDGE, Mass. , Feb. 5, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy
11:16am, Tuesday, 14'th Jan 2025
BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
11:06am, Tuesday, 14'th Jan 2025
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid p
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?
05:46am, Tuesday, 14'th Jan 2025
Blueprint Medicines (BPMC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price
Blueprint Medicines price target lowered by $11 at Wedbush, here's why
08:44am, Monday, 13'th Jan 2025
Blueprint Medicines -3.19 (-3.52%) Celldex -2.21 (-8.33%)
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
04:00pm, Sunday, 12'th Jan 2025
-- Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates -- -- Expect to achieve $
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 18'th Dec 2024
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025
-- ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM -- -- Bone density analyses reported in patients with advanced SM underscore disease-modi
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
12:37pm, Friday, 29'th Nov 2024
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?
Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
05:26pm, Friday, 15'th Nov 2024
Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion int
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
03:18pm, Thursday, 14'th Nov 2024
JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells.
BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
09:46am, Thursday, 31'st Oct 2024
Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.
Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript
02:29pm, Wednesday, 30'th Oct 2024
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief E
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
09:16am, Wednesday, 30'th Oct 2024
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $2.20 per share a year ago.
